The First Eye Cancer Working Day- Completed!
The First Eye Cancer Working Day was located at The Curie Institute, Paris, France, on June 15th, 2015. It was sponsored by The Eye Cancer Foundation, The Curie Institute and the American Joint Committee on Cancer. The Working Day was divided into several sections, each dealing with a critical problem facing our specialty. Sections begin with an overview presentation from the moderators, followed by an interactive group session to brainstorm, complete work, and plan for the next meeting. The meeting exceeded everyone's expectations. So many people attended we had to change venues twice for more and more space. Eye cancer specialists were energized and engaged in new programs to improve eye cancer care for both those with access and those without current access to eye cancer specialists. Read more about our "results" below:
Endorsements:
The First Eye Cancer Working Day is endorsed by:
Funding The Working Day event is both endorsed and hosted by The Eye Cancer Foundation (ECF) and the Curie Institute and the American Joint Committee on Cancer. ECF "Working Day" travel awards have been made available to 20 young investigators treating eye cancer patients in underserved countries.
PurposeParticipants will focus on projects that we cannot accomplish on our own and those better accomplished as a multi-center, international effort. Initiatives are directed at raising the quality of care for all eye cancer patients.
Our Work Agenda International Multi-center Working Day
8:15 – 8:30 AM: Introduction to the First Eye Cancer Working Day: Paul T Finger
8:30 - 9:30 Multi-Center, International Studies, AJCC Validation, Registries
AJCC-UICC Staging Registry Project Moderators: E. Rand Simpson, Brenda Gallie, Sarah Coupland, Svetlana Saakyan, Steffen Heegaard, Bertil Damato, Bita Esmaeli, Anna Pavlick The ongoing, retrospective multi-center, international data-sharing registry project has been completed for uveal melanoma. Currently recruiting studies include conjunctival melanoma, intraocular lymphoma, and retinoblastoma. There is a pressing need for a new registry for patients with metastatic uveal melanoma. There is still much needed work on other eye cancers. This session will be used to coordinate, recruit, and expand these initiatives.
9:30 - 10:30 Radiation Side Effect Staging Project Moderators: Wolfgang Sauerwein, Lawrence Tena, Remi Dendale, Henrike Westekemper, Carlo Mosci, Clare Stannard, Norbert Bornfeld The 2014 American Brachytherapy Society (ABS) consensus guidelines strongly suggested establishment of staging for ophthalmic radiation side effects. These guidelines can be used to compare outcomes after radiation treatment for eye cancers. This committee is tasked to create a universal staging system for ophthalmic radiation side effects.
10:30 - 11:30 Doctor Reported Outcomes (DROs) Moderators: Tero Kivela, Stefan Seregard, Santosh Honavar, Carol Shields The ocular oncology community and their patients would benefit from periodic outcome reporting. There will be privacy issues; however, multi-center cooperation for the benefit of our patients can be built stage-by-stage. Established guidelines for outcome reporting would help us better compare and thus improve our results.
1:00 - 2:00 PM Retinoblastoma "Eye Cancer" Fellowships For Underserved Countries Moderators: Laurence Desjardins, Hans Grossniklaus, Peter Gabel, Helen Dimaras, Santosh Honavar Why do 70% of children with retinoblastoma die from their cancer around the world? This is not acceptable in that less than 5% die of retinoblastoma in North America and Europe. The main difference is early detection and prompt treatment.There are many countries with no identifiable eye cancer specialist. Our community needs to develop an ongoing program to eliminate this discrepancy within 10 years. There will be discussion of funding mechanisms and coordination with existing programs.
2:00 - 3:00 Basic Surgical Techniques Moderators: Santosh Honavar, Carol Shields, Bertil Damato, Bita Esmaeli, Hans Grossniklaus, Fairooz P Manjandavida The United States Commission on Cancer (COC) recommends the development and publication of basic standard surgical techniques for the community. The work of this group will help eye cancer patients around the world. This group should define which operations need be included, assign writing groups, determine authorship and open access venues.
3:30 - 4:30 Patient Reported Outcomes (PROs) Moderators: Bertil Damato, Tara McCannel, Colin McCannel, Laura Hope-Stone, Andrea Villaroman Physicians typically measure the success of their treatments in terms of objective outcomes. However, there is a movement towards including the patient experience into the metrics driving health care decisions. This group has experience with PROs and will discuss the utility and implementation of “Patient Reported Outcomes.”
4:30 – 5:00 Summary and General Session for Future Planning: All Moderators
The 2016 Eye Cancer Working Day(s) will be hosted by Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Receive the latest news and opportunities from The Eye Cancer Foundation. Please fill out the form below.
Endorsements:
The First Eye Cancer Working Day is endorsed by:
- The International Society of Ophthalmic Oncology (ISOO)
- The American Joint Committee on Cancer (AJCC)
- The Commission on Cancer (COC)
- The American Brachytherapy Society (ABS)
- The European Ophthalmic Oncology Group (EOOG)
- The American College of Surgeons (ACS)
- The International Council of Ophthalmology (ICO)
Funding The Working Day event is both endorsed and hosted by The Eye Cancer Foundation (ECF) and the Curie Institute and the American Joint Committee on Cancer. ECF "Working Day" travel awards have been made available to 20 young investigators treating eye cancer patients in underserved countries.
PurposeParticipants will focus on projects that we cannot accomplish on our own and those better accomplished as a multi-center, international effort. Initiatives are directed at raising the quality of care for all eye cancer patients.
Our Work Agenda International Multi-center Working Day
8:15 – 8:30 AM: Introduction to the First Eye Cancer Working Day: Paul T Finger
8:30 - 9:30 Multi-Center, International Studies, AJCC Validation, Registries
AJCC-UICC Staging Registry Project Moderators: E. Rand Simpson, Brenda Gallie, Sarah Coupland, Svetlana Saakyan, Steffen Heegaard, Bertil Damato, Bita Esmaeli, Anna Pavlick The ongoing, retrospective multi-center, international data-sharing registry project has been completed for uveal melanoma. Currently recruiting studies include conjunctival melanoma, intraocular lymphoma, and retinoblastoma. There is a pressing need for a new registry for patients with metastatic uveal melanoma. There is still much needed work on other eye cancers. This session will be used to coordinate, recruit, and expand these initiatives.
9:30 - 10:30 Radiation Side Effect Staging Project Moderators: Wolfgang Sauerwein, Lawrence Tena, Remi Dendale, Henrike Westekemper, Carlo Mosci, Clare Stannard, Norbert Bornfeld The 2014 American Brachytherapy Society (ABS) consensus guidelines strongly suggested establishment of staging for ophthalmic radiation side effects. These guidelines can be used to compare outcomes after radiation treatment for eye cancers. This committee is tasked to create a universal staging system for ophthalmic radiation side effects.
10:30 - 11:30 Doctor Reported Outcomes (DROs) Moderators: Tero Kivela, Stefan Seregard, Santosh Honavar, Carol Shields The ocular oncology community and their patients would benefit from periodic outcome reporting. There will be privacy issues; however, multi-center cooperation for the benefit of our patients can be built stage-by-stage. Established guidelines for outcome reporting would help us better compare and thus improve our results.
1:00 - 2:00 PM Retinoblastoma "Eye Cancer" Fellowships For Underserved Countries Moderators: Laurence Desjardins, Hans Grossniklaus, Peter Gabel, Helen Dimaras, Santosh Honavar Why do 70% of children with retinoblastoma die from their cancer around the world? This is not acceptable in that less than 5% die of retinoblastoma in North America and Europe. The main difference is early detection and prompt treatment.There are many countries with no identifiable eye cancer specialist. Our community needs to develop an ongoing program to eliminate this discrepancy within 10 years. There will be discussion of funding mechanisms and coordination with existing programs.
2:00 - 3:00 Basic Surgical Techniques Moderators: Santosh Honavar, Carol Shields, Bertil Damato, Bita Esmaeli, Hans Grossniklaus, Fairooz P Manjandavida The United States Commission on Cancer (COC) recommends the development and publication of basic standard surgical techniques for the community. The work of this group will help eye cancer patients around the world. This group should define which operations need be included, assign writing groups, determine authorship and open access venues.
3:30 - 4:30 Patient Reported Outcomes (PROs) Moderators: Bertil Damato, Tara McCannel, Colin McCannel, Laura Hope-Stone, Andrea Villaroman Physicians typically measure the success of their treatments in terms of objective outcomes. However, there is a movement towards including the patient experience into the metrics driving health care decisions. This group has experience with PROs and will discuss the utility and implementation of “Patient Reported Outcomes.”
4:30 – 5:00 Summary and General Session for Future Planning: All Moderators
The 2016 Eye Cancer Working Day(s) will be hosted by Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Receive the latest news and opportunities from The Eye Cancer Foundation. Please fill out the form below.